The role of promoter hypermethylation in fibroblast activation and fibrogenesis

Journal of Pathology

Volumn 229, Issue 2, 2013, Pages 264-273

  Zeisberg, Elisabeth M ^a,b   Zeisberg, Michael ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

CpG islands; epigenetics; fibrosis; methylation

Indexed keywords

CPG ISLAND; DEMETHYLATION; DNA METHYLATION; EPIGENETICS; FIBROBLAST; FIBROGENESIS; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; REVIEW;

ANIMALS; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FIBROBLASTS; FIBROSIS; GENE EXPRESSION REGULATION; GENE SILENCING; HUMANS; KIDNEY; KIDNEY DISEASES; PROMOTER REGIONS, GENETIC; RAS GTPASE-ACTIVATING PROTEINS;

EID: 84871084758     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4120     Document Type: Review

References (108)

1. Zeisberg M, Neilson EG,. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 2010; 21: 1819-1834.
2. Strutz F, Zeisberg M,. Renal fibroblasts and myofibroblasts in chronic kidney disease. J Am Soc Nephrol 2006; 17: 2992-2998. (Pubitemid 44707759)
3. Zeisberg M, Strutz F, Muller GA,. Role of fibroblast activation in inducing interstitial fibrosis. J Nephrol 2000; 13 (suppl 3): S111-120.
4. Kalluri R, Zeisberg M., Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401.
5. Zeisberg M, Strutz F, Muller GA,. Renal fibrosis: an update. Curr Opin Nephrol Hypertens 2001; 10: 315-320. (Pubitemid 32424018)
6. Alvarez RJ, Sun MJ, Haverty TP, et al,. Biosynthetic and proliferative characteristics of tubulointerstitial fibroblasts probed with paracrine cytokines. Kidney Int 1992; 41: 14-23.
7. Strutz F, Zeisberg M, Hemmerlein B, et al,. Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation. Kidney Int 2000; 57: 1521-1538. (Pubitemid 30207911)
8. Gardner H, Broberg A, Pozzi A, et al,. Absence of integrin α1β1 in the mouse causes loss of feedback regulation of collagen synthesis in normal and wounded dermis. J Cell Sci 1999; 112: 263-272. (Pubitemid 29080649)
9. Vogel W, Gish GD, Alves F, et al,. The discoidin domain receptor tyrosine kinases are activated by collagen. Mol Cell 1997; 1: 13-23. (Pubitemid 127376389)
10. Chen X, Abair TD, Ibanez MR, et al,. Integrin α1β1 controls reactive oxygen species synthesis by negatively regulating epidermal growth factor receptor-mediated Rac activation. Mol Cell Biol 2007; 27: 3313-3326. (Pubitemid 46685210)
11. Lam S, Verhagen NA, Strutz F, et al,. Glucose-induced fibronectin and collagen type III expression in renal fibroblasts can occur independent of TGF-β1. Kidney Int 2003; 63: 878-888. (Pubitemid 36315565)
12. Spurgeon KR, Donohoe DL, Basile DP,. Transforming growth factor-β in acute renal failure: receptor expression, effects on proliferation, cellularity, and vascularization after recovery from injury. Am J Physiol Renal Physiol 2005; 288: F568-577. (Pubitemid 40279464)
13. Forbes JM, Leaker B, Hewitson TD, et al,. Macrophage and myofibroblast involvement in ischemic acute renal failure is attenuated by endothelin receptor antagonists. Kidney Int 1999; 55: 198-208. (Pubitemid 29004251)
14. Villanueva S, Cespedes C, Vio CP,. Ischemic acute renal failure induces the expression of a wide range of nephrogenic proteins. Am J Physiol Regul Integr Comp Physiol 2006; 290: R861-870.
15. Broekema M, Harmsen MC, van Luyn MJ, et al,. Bone marrow-derived myofibroblasts contribute to the renal interstitial myofibroblast population and produce procollagen I after ischemia/reperfusion in rats. J Am Soc Nephrol 2007; 18: 165-175. (Pubitemid 46053430)
16. Bonventre JV,. Pathophysiology of AKI: injury and normal and abnormal repair. Contrib Nephrol 2010; 165: 9-17.
17. Thadhani R, Pascual M, Bonventre JV,. Acute renal failure. N Engl J Med 1996; 334: 1448-1460. (Pubitemid 126590563)
18. 2/M mediates kidney fibrosis after injury. Nat Med 2010; 16: 535-543.
19. Bechtel W, McGoohan S, Zeisberg EM, et al,. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med 2010; 16: 544-550.
20. Muller GA, Rodemann HP,. Characterization of human renal fibroblasts in health and disease: I. Immunophenotyping of cultured tubular epithelial cells and fibroblasts derived from kidneys with histologically proven interstitial fibrosis. Am J Kidney Dis 1991; 17: 680-683.
21. Rodemann HP, Muller GA,. Characterization of human renal fibroblasts in health and disease: II. In vitro growth, differentiation, and collagen synthesis of fibroblasts from kidneys with interstitial fibrosis. Am J Kidney Dis 1991; 17: 684-686.
22. Weber KT, Brilla CG,. Factors associated with reactive and reparative fibrosis of the myocardium. Basic Res Cardiol 1992; 87 (suppl 1): 291-301.
23. Hinz B, Phan SH, Thannickal VJ, et al,. The myofibroblast: one function, multiple origins. Am J Pathol 2007; 170: 1807-1816. (Pubitemid 47339255)
24. Lafyatis R., Targeting fibrosis in systemic sclerosis. Endocr Metab Immune Disord Drug Targets 2006; 6: 395-400. (Pubitemid 44941927)
25. Orimo A, Gupta PB, Sgroi DC, et al,. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-348. (Pubitemid 40692295)
26. Wu C, Morris JR,. Genes, genetics, and epigenetics: a correspondence. Science 2001; 293: 1103-1105. (Pubitemid 32758084)
27. Bernstein BE, Meissner A, Lander ES,. The mammalian epigenome. Cell 2007; 128: 669-681. (Pubitemid 46273573)
28. Herman JG, Baylin SB,. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042-2054. (Pubitemid 37448928)
29. Boyer LA, Mathur D, Jaenisch R,. Molecular control of pluripotency. Curr Opin Genet Dev 2006; 16: 455-462. (Pubitemid 44345206)
30. Bird AP, Wolffe AP,. Methylation-induced repression-belts, braces, and chromatin. Cell 1999; 99: 451-454. (Pubitemid 129746827)
31. Estecio MR, Issa JP,. Dissecting DNA hypermethylation in cancer. FEBS Lett 2011; 585: 2078-2086.
32. Mohn F, Weber M, Rebhan M, et al,. Lineage-specific polycomb targets and de novo DNA methylation define restriction and potential of neuronal progenitors. Mol Cell 2008; 30: 755-766.
33. Schulz WA, Steinhoff C, Florl AR,. Methylation of endogenous human retroelements in health and disease. Curr Top Microbiol Immunol 2006; 310: 211-250. (Pubitemid 47400292)
34. Yoder JA, Walsh CP, Bestor TH,. Cytosine methylation and the ecology of intragenomic parasites. Trends Genet 1997; 13: 335-340. (Pubitemid 27309911)
35. Yamada Y, Jackson-Grusby L, Linhart H, et al,. Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. Proc Natl Acad Sci USA 2005; 102: 13580-13585. (Pubitemid 41420891)
36. Shenker N, Flanagan JM,. Intragenic DNA methylation: implications of this epigenetic mechanism for cancer research. Br J Cancer 2012; 106: 248-253.
37. Hellman A, Chess A,. Gene body-specific methylation on the active X chromosome. Science 2007; 315: 1141-1143. (Pubitemid 46328027)
38. Ball MP, Li JB, Gao Y, et al,. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol 2009; 27: 361-368.
39. Maunakea AK, Nagarajan RP, Bilenky M, et al,. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 2010; 466: 253-257.
40. Shukla S, Kavak E, Gregory M, et al,. CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing. Nature 2011; 479: 74-79.
41. Parry L, Clarke AR,. The roles of the methyl-CpG binding proteins in cancer. Genes Cancer 2011; 2: 618-630.
42. Nan X, Ng HH, Johnson CA, et al,. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998; 393: 386-389. (Pubitemid 28269714)
43. Bracaglia G, Conca B, Bergo A, et al,. Methyl-CpG-binding protein 2 is phosphorylated by homeodomain-interacting protein kinase 2 and contributes to apoptosis. EMBO Rep 2009; 10: 1327-1333.
44. Jin Y, Ratnam K, Chuang PY, et al,. A systems approach identifies HIPK2 as a key regulator of kidney fibrosis. Nat Med 2012; 18: 580-588.
45. Sansom OJ, Maddison K, Clarke AR,. Mechanisms of disease: methyl-binding domain proteins as potential therapeutic targets in cancer. Nat Clin Pract Oncol 2007; 4: 305-315. (Pubitemid 46758788)
46. Wang Z, Zhang J, Zhang Y, et al,. SPAN-XB core promoter sequence is regulated in myeloma cells by specific CpG dinucleotides associated with the MeCP2 protein. Int J Cancer 2006; 119: 2878-2884. (Pubitemid 44846240)
47. Jenkins Y, Markovtsov V, Lang W, et al,. Critical role of the ubiquitin ligase activity of UHRF1, a nuclear RING finger protein, in tumor cell growth. Mol Biol Cell 2005; 16: 5621-5629. (Pubitemid 41752212)
48. Sharif J, Muto M, Takebayashi S, et al,. The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. Nature 2007; 450: 908-912. (Pubitemid 350231331)
49. Bostick M, Kim JK, et al,. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science 2007; 317: 1760-1764. (Pubitemid 47461842)
50. Prokhortchouk A, Hendrich B, Jorgensen H, et al,. The p120 catenin partner Kaiso is a DNA methylation-dependent transcriptional repressor. Genes Dev 2001; 15: 1613-1618. (Pubitemid 32702582)
51. Filion GJ, Zhenilo S, Salozhin S, et al,. A family of human zinc finger proteins that bind methylated DNA and repress transcription. Mol Cell Biol 2006; 26: 169-181.
52. Toyota M, Ahuja N, Ohe-Toyota M, et al,. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999; 96: 8681-8686. (Pubitemid 29354851)
53. 2+ oscillations. EMBO J 2004; 23: 1749-1760. (Pubitemid 38649638)
54. Kolfschoten IG, van Leeuwen B, Berns K, et al,. A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell 2005; 121: 849-858. (Pubitemid 40806417)
55. Tao H, Huang C, Yang JJ, et al,. MeCP2 controls the expression of RASAL1 in the hepatic fibrosis in rats. Toxicology 2011; 290: 327-333.
56. Ohta M, Seto M, Ijichi H, et al,. Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression. Gastroenterology 2009; 136: 206-216.
57. 2+-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers. Proc Natl Acad Sci USA 2007; 104: 12353-12358. (Pubitemid 47206141)
58. Bian EB, Huang C, Ma TT, et al,. DNMT1-mediated PTEN hypermethylation confers hepatic stellate cell activation and liver fibrogenesis in rats. Toxicol Appl Pharmacol 2012; 264: 13-22
59. Mann J, Chu DC, Maxwell A, et al,. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology 2010; 138: 705-714, 14 e1-4.
60. Li J, Yen C, Liaw D, et al,. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-1947. (Pubitemid 27148818)
61. Yao YJ, Ping XL, Zhang H, et al,. PTEN/MMAC1 mutations in hepatocellular carcinomas. Oncogene 1999; 18: 3181-3185. (Pubitemid 29261240)
62. Cui W, Matsuno K, Iwata K, et al,. NOX1/nicotinamide adenine dinucleotide phosphate, reduced form (NADPH) oxidase promotes proliferation of stellate cells and aggravates liver fibrosis induced by bile duct ligation. Hepatology 2011; 54: 949-958.
63. Takenaka K, Gemma A, Yoshimura A, et al,. Reduced transcription of the Smad4 gene during pulmonary carcinogenesis in idiopathic pulmonary fibrosis. Mol Med Rep 2009; 2: 73-80.
64. Wang Y, Fan PS, Kahaleh B,. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006; 54: 2271-2279. (Pubitemid 44051084)
65. Cairns P, Okami K, Halachmi S, et al,. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997; 57: 4997-5000. (Pubitemid 27498107)
66. Aitchison AA, Veerakumarasivam A, Vias M, et al,. Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. Prostate 2008; 68: 661-674. (Pubitemid 351614644)
67. Graff JR, Herman JG, Lapidus RG, et al,. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 1995; 55: 5195-5199.
68. Pan J, Zhong J, Gan LH, et al,. Klotho, an anti-senescence related gene, is frequently inactivated through promoter hypermethylation in colorectal cancer. Tumour Biol 2011; 32: 729-735.
69. Wang L, Wang X, Jie P, et al,. Klotho is silenced through promoter hypermethylation in gastric cancer. Am J Cancer Res 2011; 1: 111-119.
70. Esteller M, Corn PG, Baylin SB, et al,. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225-3229. (Pubitemid 32695003)
71. Esteller M, Cordon-Cardo C, et al,. p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res 2001; 61: 2816-2821. (Pubitemid 32691917)
72. Oster B, Thorsen K, Lamy P, et al,. Identification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas. Int J Cancer 2011; 129: 2855-2866.
73. Lung HL, Bangarusamy DK, Xie D, et al,. THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma. Oncogene 2005; 24: 6525-6532. (Pubitemid 41486635)
74. Sugino Y, Misawa A, Inoue J, et al,. Epigenetic silencing of prostaglandin E receptor 2 (PTGER2) is associated with progression of neuroblastomas. Oncogene 2007; 26: 7401-7413. (Pubitemid 350158713)
75. Yoder JA, Soman NS, Verdine GL, et al,. DNA (cytosine-5)- methyltransferases in mouse cells and tissues. Studies with a mechanism-based probe. J Mol Biol 1997; 270: 385-395.
76. Kar S, Deb M, Sengupta D, et al,. An insight into the various regulatory mechanisms modulating human DNA methyltransferase 1 stability and function. Epigenetics 2012; 7: 994-1007.
77. Arand J, Spieler D, Karius T, et al,. In vivo control of CpG and non-CpG DNA methylation by DNA methyltransferases. PLoS Genet 2012; 8: e1002750.
78. Damiani LA, Yingling CM, Leng S, et al,. Carcinogen-induced gene promoter hypermethylation is mediated by DNMT1 and causal for transformation of immortalized bronchial epithelial cells. Cancer Res 2008; 68: 9005-9014.
79. Jair KW, Bachman KE, Suzuki H, et al,. De novo CpG island methylation in human cancer cells. Cancer Res 2006; 66: 682-692. (Pubitemid 43165930)
80. Choi SH, Heo K, Byun HM, et al,. Identification of preferential target sites for human DNA methyltransferases. Nucleic Acids Res 2011; 39: 104-118.
81. Feltus FA, Lee EK, Costello JF, et al,. Predicting aberrant CpG island methylation. Proc Natl Acad Sci USA 2003; 100: 12253-12258. (Pubitemid 37271547)
82. Itzykson R, Fenaux P,. Optimizing hypomethylating agents in myelodysplastic syndromes. Curr Opin Hematol 2012; 19: 65-70.
83. Delhommeau F, Dupont S, Della Valle V, et al,. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289-2301.
84. Langemeijer SM, Kuiper RP, Berends M, et al,. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009; 41: 838-842.
85. Ko M, Huang Y, Jankowska AM, et al,. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010; 468: 839-843.
86. Kosmider O, Gelsi-Boyer V, Slama L, et al,. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 2010; 24: 1094-1096.
87. Ward PS, Patel J, Wise DR, et al,. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17: 225-234.
88. Shen L, Kantarjian H, Guo Y, et al,. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010; 28: 605-613.
89. Foulks JM, Parnell KM, Nix RN, et al,. Epigenetic drug discovery: targeting DNA methyltransferases. J Biomol Screen 2012; 17: 2-17.
90. Ma JY, Liang XW, Schatten H, Sun QY,. Active DNA demethylation in mammalian preimplantation embryos: new insights and new perspectives. Mol Hum Reprod 2012; 18: 333-340.
91. Lin SL,. Concise review: Deciphering the mechanism behind induced pluripotent stem cell generation. Stem Cells 2011; 29: 1645-1649.
92. Dhe-Paganon S, Syeda F, Park L,. DNA methyl transferase 1: regulatory mechanisms and implications in health and disease. Int J Biochem Mol Biol 2011; 2: 58-66.
93. Bhutani N, Burns DM, Blau HM,. DNA demethylation dynamics. Cell 2011; 146: 866-872.
94. Tahiliani M, Koh KP, Shen Y, et al,. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009; 324: 930-935.
95. Ito S, D'Alessio AC, Taranova OV, et al,. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010; 466: 1129-1133.
96. Guo JU, Su Y, Zhong C, et al,. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 2011; 145: 423-434.
97. Cortellino S, Xu J, Sannai M, et al,. Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell 2011; 146: 67-79.
98. Rai K, Huggins IJ, James SR, et al,. DNA demethylation in zebrafish involves the coupling of a deaminase, a glycosylase, and gadd45. Cell 2008; 135: 1201-1212.
99. Ingrosso D, Cimmino A, Perna AF, et al,. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet 2003; 361: 1693-1699. (Pubitemid 36577442)
100. Nanayakkara PW, Kiefte-de Jong JC, Stehouwer CD, et al,. Association between global leukocyte DNA methylation, renal function, carotid intima-media thickness and plasma homocysteine in patients with stage 2-4 chronic kidney disease. Nephrol Dial Transpl 2008; 23: 2586-2592.
101. Stenvinkel P, Karimi M, Johansson S, et al,. Impact of inflammation on epigenetic DNA methylation-a novel risk factor for cardiovascular disease? J Intern Med 2007; 261: 488-499. (Pubitemid 46587721)
102. Sapienza C, Lee J, Powell J, et al,. DNA methylation profiling identifies epigenetic differences between diabetes patients with ESRD and diabetes patients without nephropathy. Epigenetics 2011; 6: 20-28.
103. Zeybel M, Hardy T, Wong YK, et al,. Multigenerational epigenetic adaptation of the hepatic wound-healing response. Nat Med 2012 (in press).
104. Sun CY, Chang SC, Wu MS,. Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation. Kidney Int 2012; 81: 640-650.
105. Cisneros J, Hagood J, Checa M, et al,. Hypermethylation-mediated silencing of p14ARF in fibroblasts from idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2012; 303: L295-303.
106. Sanders YY, Pardo A, Selman M, et al,. Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis. Am J Respir Cell Mol Biol 2008; 39: 610-618.
107. Wu CH, Tang SC, Wang PH, et al,. Nickel-induced epithelial-mesenchymal transition by reactive oxygen species generation and E-cadherin promoter hypermethylation. J Biol Chem 2012; 287: 25292-25302.
108. Huang SK, Fisher AS, Scruggs AM, et al,. Hypermethylation of PTGER2 confers prostaglandin E2 resistance in fibrotic fibroblasts from humans and mice. Am J Pathol 2010; 177: 2245-2255.